Sichuan Kelun-Biotech Biopharmaceutical
Tracked across 2 events · 20 articles · First seen May 30, 2026 · Last active Jun 03, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Tech
Sichuan Kelun-Biotech Biopharmaceutical announced the positive first-in-human study results for its novel B7-H3 ADC SKB500 at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, United States. Professor Liu Haifeng from Jilin Provincial…
Impact: Sichuan Kelun-Biotech Biopharmaceutical announced positive first-in-human study results for its novel B7-H3 ADC SKB500, which could significantly boost its market position and future revenue streams.
Jun 03, 2026 · 6 articles
Tech
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced positive results from its Phase III OptiTROP-Lung05 clinical study for sacituzumab tirumotecan (sac-TMT) in combination with pembrolizumab (KEYTRUDA) as a first-line treatment for non-small cell lung cancer (NSCLC). The…
Impact: The company announced positive Phase III clinical trial results for sac-TMT, a core product, which significantly prolonged progression-free survival in NSCLC patients. This enhances its product pipeline and market position.
May 30, 2026 · 14 articles
100
Sichuan Kelun-Biotech Biopharmaceutical announced resultsKelun-Biotech sac-TMT...
100
Sichuan Kelun-Biotech Biopharmaceutical announced study resultsSichuan Kelun-Biotech...
70
Sichuan Kelun-Biotech Biopharmaceutical licensed rights Merck & Co.Kelun-Biotech sac-TMT...
NEWSDESK
Track Sichuan Kelun-Biotech Biopharmaceutical live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard